4//SEC Filing
Enyedy Mark J 4
Accession 0001415889-24-002871
CIK 0000855654other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 9:42 PM ET
Size
9.4 KB
Accession
0001415889-24-002871
Insider Transaction Report
Form 4
ImmunoGen, Inc.IMGN
Enyedy Mark J
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2024-02-02+51,234→ 604,504 total - Exercise/Conversion
Restricted Stock Unit
2024-02-02−51,234→ 102,466 totalExercise: $0.00→ Common Stock (51,234 underlying) - Sale
Common Stock
2024-02-05$29.28/sh−20,107$588,733→ 584,397 total
Footnotes (4)
- [F1]Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.25 to $29.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
- [F3]Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- [F4]The RSUs were granted on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.
Documents
Issuer
ImmunoGen, Inc.
CIK 0000855654
Entity typeother
Related Parties
1- filerCIK 0001586965
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 9:42 PM ET
- Size
- 9.4 KB